CRISPR Therapeutics (NASDAQ:CRSP) shares were on track to snap six straight sessions of losses on Wednesday, as the stock rose over 2% to $34.03 in afternoon trade. The Switzerland-based biotech ...

Recursion Pharmaceuticals uses artificial intelligence (AI) in its proprietary operating system to match new compounds ...

A recent study showcases the power of CRISPR gene editing to significantly boost the production of resveratrol, a ...

Bullish option flow detected in Crispr Therapeutics (CRSP) with 4,723 calls trading, 2x expected, and implied vol increasing over 3 points to ...

CRISPR Therapeutics (NasdaqGM:CRSP) recently announced the departure of Chief Operating Officer Julianne Bruno, reflecting a notable leadership change that could influence its operational direction.

A team of researchers at Karolinska Institutet has developed a novel tool for genetic research. The study, published in ...

Corient Private Wealth LLC lessened its holdings in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 4.0% during the ...

CRISPR Therapeutics poised for growth with international potential and clinical assets. Read why I rate CRSP stock a Strong ...

The plant breeding and CRISPR plants market is estimated at USD 8.91 billion in 2025 and is projected to reach USD 13.86 ...

Advances in the gene-editing technology known as CRISPR-Cas9 over the past 15 years have yielded important new insights into ...

Learn more about whether Alvotech or CRISPR Therapeutics AG is a better investment based on AAII's A+ Investor grades, which ...